Janssen shakes up reimbursement

Posted 18 May 2022 AM

The federal government should reimburse some innovative medicines for cancer and rare diseases before they finish Phase III trials and while HTA processes are still in negotiation, according to a report released by Janssen.

Titled Accelerating Access to Innovative Medicines and prepared for Janssen by Biointelect, the report has recommendations for conditional listing arrangements to provide rapid, reimbursed access to medicines that address areas of high unmet need and have been passed by the TGA provisional pathway.

To see the whole article, please login